Author

S. Marfil

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 6 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Organism:mouse· 2 Organism:non-human primate· 1 Organism:plant (other)· 1

Frequent Co-Authors

J. Blanco· 8 shared E. Pradenas· 7 shared B. Trinite· 5 shared J. Segales· 5 shared J. Vergara-Alert· 5 shared B. Clotet· 4 shared C. Rovirosa· 4 shared F. Tarres-Freixas· 4 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersImmunology

J. Blanco

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

J. Carrillo, C. Avila-Nieto, J. Vergara-Alert, P. Amengual-Rigo, E. Ainsua-Enrich, M. Brustolin, M. L. Rodriguez de la Concepcion, N. Pedreno-Lopez, J. Rodon, V. Urrea, E. Pradenas, S. Marfil, E. Ballana, E. Riveira-Munoz, M. Perez, , J. Segales

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

bioRxiv · Jul 7, 2023Immunology

A Novel Monoclonal Antibody Targeting a Large Surface of the Receptor Binding Motif Shows Pan-neutralizing SARS-CoV-2 Activity Including BQ.1.1 Variant

L. de Campos-Mata, B. Trinite, A. Modrego, S. Tejedor Vaquero, E. Pradenas, N. Rodrigo Melero, D. Carlero, S. Marfil, A. Pons-Grifols, M. T. Bueno-Carrasco, C. Santiago, F. Tarres-Freixas, V. Urrea, N. Izquierdo, E. Riveira-Munoz, , G. Magri

This study characterizes a new monoclonal antibody, 17T2, that broadly neutralizes SARS-CoV-2 variants, including BQ.1.1, and shows in vivo prophylactic activity against Omicron BA.1.1.

bioRxiv · Jan 20, 2023 · PreprintImmunology

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

A. Moros, A. Prefaneta, A. Barreiro, E. Perozo, A. Fernandez, M. Canete, L. Gonzalez, C. Garriga, E. Pradenas, S. Marfil, J. Blanco, P. Cebollada-Rica, M. Sistere-Oro, A. Meyerhans, T. Prat Cabanas, , L. Ferrer

This study evaluates the immunogenicity and safety of PHH-1V, a SARS-CoV-2 RBD fusion vaccine in pigs, showing a robust immune response and good safety profile.

bioRxiv · Jan 19, 2023Immunology

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

A. Prenafeta, G. Bech-Sabat, S. Moros, A. Barreiro, A. Fernandez, M. Canete, M. Roca, L. Gonzalez, C. Garriga, J. Confais, M. Toussenot, H. Contamin, A. Pizzorno, M. Rosa-Calatrava, E. Pradenas, , L. Ferrer

This study evaluates the PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates, showing high antibody levels, balanced cellular immunity, and reduced viral load.

bioRxiv · Dec 13, 2022Immunology

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

A. Barreiro, A. Prenafeta, G. Bech-Sabat, M. Roca, E. Perozo, R. March, L. Gonzalez-Gonzalez, L. Madrenas, J. Corominas, A. Fernandez, A. Moros, M. Molas, T. Pentinat-Pelegrin, C. Panosa, A. Moreno, , Barr

This paper evaluates a recombinant RBD fusion heterodimer vaccine in mice, showing 100% efficacy against SARS-CoV-2 variants and neutralizing antibodies.

bioRxiv · Nov 22, 2021Immunology

The characteristics of the HIV-1 Env glycoprotein contribute to viral pathogenesis

S. Perez-Yanes, M. Pernas, S. Marfil, R. Cabrera-Rodriguez, R. Ortiz, C. Rovirosa, J. Estevez-Herrera, I. Olivares, C. Casado, C. Lopez-Galindez, J. Blanco, A. Valenzuela-Fernandez

This study examines how HIV-1 Env glycoprotein characteristics correlate with viral pathogenesis by comparing functional and sequence features across different clinical progression groups.

bioRxiv · Jul 7, 2021 · PreprintMicrobiology

Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.

B. Trinite, E. Pradenas, S. Marfil, C. Rovirosa, V. Urrea, F. Tarres-Freixas, R. Ortiz, J. Vergara-Alert, J. Segales, V. Guallar, A. Lepore, N. Izquierdo-Useros, G. Trujillo, J. Trape, C. Gonzalez-Fernandez, , J. Blanco

The paper assesses how prior SARS-CoV-2 infection affects B.1.1.7 cross-neutralization in vaccinated individuals, finding that previously infected individuals show equivalent neutralization against B.1.1.7 compared to the Wuhan strain.

bioRxiv · Mar 5, 2021Immunology

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

E. Pradenas, B. Trinite, V. Urrea, S. Marfil, C. Avila-Nieto, M. L. Rodriguez de la Concepcion, F. Tarres-Freixas, S. Perez-Yanes, C. Rovirosa, E. Ainsua-Enrich, J. Rodon, J. Vergara-Alert, J. Sagales, V. Guallar, A. Valencia, , J. Blanco

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

bioRxiv · Nov 22, 2020Immunology